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Abstract
Relapse is the rule rather than the exception among smokers attempting to quit, and compared to 
men, women may have higher relapse rates. The current study was a randomized clinical trial 
testing a palmtop computer-delivered treatment for smoking relapse prevention among women. 
The intervention was individualized based on key theoretical constructs that were measured using 
ecological momentary assessment (EMA). All participants (N=302) received standard smoking 
cessation treatment consisting of nicotine replacement therapy and group counseling, and 
completed EMA procedures for one week after quitting. At the completion of the group 
counseling sessions and EMA procedures, participants were randomized to either computer-
delivered treatment (CDT) or no further computer-delivered treatment or assessment (EMA-Only). 
CDT participants received a palmtop computer-delivered relapse prevention treatment for one 
additional month. CDT did not improve abstinence rates relative to EMA-Only. Process analyses 
suggested that heavier smokers were more likely to use CDT and that greater use among CDT 
participants may be associated with more positive outcomes. The rapid pace of technological 
advances in mobile computer technology and the ubiquity of such devices provide a novel 
platform for developing new and potentially innovative treatments. However, the current study did 
not demonstrate the efficacy of such technology in improving treatment outcomes.
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Although smoking cessation can dramatically reduce the risk of tobacco-related disease 
(USDHHS, 2001), relapse is the rule rather than the exception among smokers attempting to 
quit with rates as high as 70–90%, even among smokers who have been abstinent for a week 
or longer (Brandon, Tiffany, Obremski, & Baker, 1990; Garvey, Bliss, Hitchcock, Heinold, 
& Rosner, 1992). Although there is not a consensus, there is evidence suggesting that 
women have higher relapse rates than do men (Wetter et al., 1999) and a recent meta-
analysis found that women had higher relapse rates than men across all conventional forms 
of treatment (Scharf & Shiffman, 2004). Thus, the development of effective relapse 
prevention treatments has been identified as a priority in reducing smoking among women 
(USDHHS, 2001).
Social cognitive theory (Bandura, 1986) posits that key variables influencing relapse include 
affective state, self-efficacy, drug and coping outcome expectancies, and coping behaviors 
(Marlatt & Donovan, 2005). However, relapse prevention interventions based on social 
cognitive theory have not yielded consistently superior results relative to other treatment 
approaches (Carroll, 1996; Hajek, Stead, West, Jarvis, & Lancaster, 2009). One possible 
strategy for improving the efficacy of relapse prevention interventions is to combat relapse 
precipitants in real-time during acute episodes of high risk (Carter, Day, Cinciripini, & 
Wetter, 2007; Shiffman, 2006), congruent with an “episodic” model of relapse (Shiffman, 
1989). Real-time treatment might also strengthen adaptive behaviors through repeated 
exposure and repetition of coping strategies, which could contribute to better acquisition, 
retention, and use of such skills over time. One strategy for delivering a behavioral relapse 
prevention intervention in real-time is with the use of palmtop personal computers (PPCs) 
such as smartphones or personal digital assistants (Carter, Day, Cinciripini, & Wetter, 2007).
PPCs have been used extensively for ecological momentary assessment (EMA). EMA 
provides a means to collect data in real time in the real world, and EMA research has 
supported the basic propositions of social cognitive theory, as well as highlighted the 
dynamic nature of the relapse process (Gwaltney, Shiffman, Balabani & Paty, 2005; 
Shiffman et al., 2000). Because retrospective recall of cognitions and behaviors surrounding 
temptations and lapses can be poor and biased (Shiffman, 2005; Stone & Shiffman, 1994), 
EMA may provide more accurate data for individualization of treatment than data based on 
traditional self-report approaches (e.g., a PPC-delivered intervention could be individualized 
based on key theoretical constructs assessed during actual high risk situations, as well as 
allow for real-time modifications in the treatment program as individuals move through the 
process of quitting).
A critical advantage of a PPC-delivered intervention is unparalleled access to context-
specific quitting strategies in real-time (Carter, Day, Cinciripini, & Wetter, 2007). Moreover, 
A PPC-delivered intervention might lead to improved abstinence rates for other reasons as 
well. For example, negative affect interferes with the performance of coping behaviors 
(Drobes, Meier, & Tiffany, 1994), perhaps by occupying cognitive workspace (Drobes, 
Elibero, & Evans, 2006), and is a powerful predictor of relapse (Wetter et al., 1999). A real-
time intervention may be able to counteract the effects of negative affect on coping behavior 
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and relapse by directly recommending relevant and appropriate context-specific coping 
strategies, and by eliminating the need for a search of memory (with perhaps the exception 
of remembering to use the PPC). Given the prominence that negative affect has often been 
assigned in explaining gender differences in relapse (Walitzer & Dearing, 2006), 
interventions designed to increase coping during the experience of negative affect could be 
particularly important for women.
The current study tested a real-time, theoretically-based, PPC-delivered treatment for 
smoking relapse prevention among women. The intervention was individualized for each 
woman based on key theoretical constructs derived from social cognitive theory and 
assessed using EMA. A recent review concluded that incorporating EMA into health 
behavior interventions using mobile technology should be a major focus of future research 
(Heron & Smyth, 2010).
Method
Study Design
WIN (Women’s INtervention) was a randomized clinical trial evaluating the efficacy of a 
PPC-delivered relapse prevention intervention for female smokers (N=302). All participants 
received standard smoking cessation treatment consisting of group counseling and six weeks 
of nicotine replacement therapy (NRT; nicotine patches). All participants completed EMA 
procedures during the week immediately following the quit date. All group counseling 
sessions and EMA procedures ended on postcessation Day 7. Following completion of the 
group counseling and EMA procedures on Day 7, participants were randomized to either 
computer-delivered treatment (CDT; n = 151) or standard treatment (EMA-Only; n = 151). 
CDT participants then utilized the PPC to receive an individualized relapse prevention 
intervention for one additional month (from Day 7 until Day 35 postcessation). All 
participants were followed for one year postcessation. This research was approved by the 
Institutional Review Boards at both the University of Texas M.D. Anderson Cancer Center 
and Group Health Research Institute.
Participants
Participants were recruited from the Seattle metropolitan area from 1999 to 2002 using 
advertisements (local newspapers, radio, bus), public service announcements, and fliers in 
local clinics. Follow-up was completed in 2003. Individuals were screened for eligibility 
criteria over the telephone, and eligible respondents attended an orientation during which a 
detailed study overview was provided, informed consent was obtained, and eligibility 
criteria were finalized. Inclusion criteria were: female; aged 18 to 70 years; current smoking 
of at least 10 cigarettes per day for at least the past year; expired breath carbon monoxide 
(CO) level of 10 parts per million (ppm) or greater; and the ability to speak, read, and write 
in English. Exclusion criteria were: regular use of tobacco other than cigarettes; active 
substance abuse disorder, major depression, anxiety disorder, or eating disorder; current use 
of bupropion; and contraindications for NRT. A modified version of the Primary Care 
Evaluation of Mental Disorders (PRIME-MD; Spitzer et al., 1995) was used to screen for 
psychiatric disorders. Ineligible respondents were referred to other smoking cessation 
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programs. As shown in Figure 1, 739 individuals made inquiries about the study, and 302 
were eligible, consented to participate, and randomized to treatment.
Procedure
At orientation, clinic visits were scheduled three days before the quit date (Pre-Quit Day -3), 
Pre-Quit Day -1, three days after the quit date (Day 3), Day 5, Day 7, and Day 35; and 
follow-up visits 6 and 12 months post-quit day. During each visit, participants completed 
questionnaires and provided a breath sample to measure CO level. At Pre-Quit Day -1, all 
participants received a PPC and were asked to complete EMA assessments for one week 
(until Day 7). EMA procedures were identical for all participants and were completed prior 
to randomization. After completion of all counseling sessions and EMA procedures at Day 
7, participants were randomly assigned to CDT or EMA-Only after stratification for race, 
cigarettes smoked per day, and depression history. Data collected using EMA were used to 
individualize the PPC-delivered treatment for each woman in CDT. The study biostatistician 
generated the randomization sequence.
EMA Procedures and Measures
The Casio E-10 PPC was used, with custom software developed specifically for the study. 
All participants received the PPC at Pre-Quit Day -1, were trained in its use, and completed 
PPC-based assessments for one week in response to random prompts (four per day), as well 
as each time they experienced an urge to smoke (temptation assessments). Participants 
received gift certificates based on their completion rate for random assessments: $10 for 50–
69% completion, $25 for 70–89% completion, and $50 for 90% or more completion.
During the course of the first 7 postcessation days, the EMA program delivered 7,381 
random prompts and 5,746 were completed (78% compliance). Participants completed 5,062 
temptation assessments, an average of 17.10 temptation assessments per person for the week 
(SD = 11.20) and 2.44 temptation assessments per person per day (SD = 1.60). Four 
participants did not provide any temptation assessments. There were no significant 
differences in compliance with EMA between the participants who were later randomized to 
EMA-Only or CDT.
Situation Types—EMA items for the random prompts and temptation episodes assessed 
three critical dimensions of high-risk situations: 1) presence/absence of negative affect, 2) 
availability/unavailability of cigarettes, and 3) presence/absence of alcohol use or a plan to 
use alcohol. Dimensions were selected based on both the empirical relation of the dimension 
to relapse and the ability to delineate specific coping strategies tailored to the dimension. 
These dimensions defined eight possible “types” of high-risk situations (e.g., presence/
absence of negative mood × availability/unavailability of cigarettes × presence/absence of 
alcohol use).
Coping Strategies—For each type of situation, the PPC displayed 10 situation-specific 
coping strategies. Strategies for each of the eight situations were generated by a pool of five 
smoking cessation experts. Strategies were then rated by the experts with respect to their 
efficacy in each of the eight situations and the top ten strategies for each situation were 
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retained. Coping strategies were common cognitive and behavioral strategies for abstaining 
from smoking. Cognitive strategies included distraction, self-efficacy enhancement, and 
reminders of smoking consequences. Behavioral strategies included problem-solving, direct 
action, escaping the situation, assertiveness, soliciting social support, substituting behavior, 
and relaxation. For example, if a participant reported that she was experiencing negative 
affect, but cigarettes were not available and alcohol was not used, coping strategies such as 
relaxation and soliciting social support were presented. If the participant’s report reflected 
drinking alcohol and other people smoking, but no negative affect, coping strategies such as 
escaping the situation and moderating alcohol use were presented. The final pool of coping 
strategies included 63, rather than 80, strategies as some coping techniques were applicable 
to several types of high risk situations.
Efficacy and Outcome Expectations—For each of the ten situation-specific coping 
strategies, efficacy (participant’s confidence that she could perform the strategy) and 
outcome (whether the strategy would help her maintain abstinence) expectations were 
assessed.
EMA Tailoring Algorithm—Based on the EMA data collected during the first week 
postcessation, an individualized hierarchy of coping strategies for each of the eight high-risk 
situations was generated for each woman in CDT. Strategies within each situation type were 
ordered based on the mean efficacy and outcome expectation ratings for that strategy using a 
specific algorithm. The algorithm is available from the authors upon request.
Treatment
All Participants—All participants (both EMA-Only and CDT) received two group 
counseling sessions prior to quitting and three after quitting (i.e., Pre-Quit Day -3 through 
Day 7), and six weeks of the 21-mg nicotine patch (Nicoderm CQ; GlaxoSmithKline).
Computer-Delivered Treatment (CDT)—CDT participants received PPC-delivered 
treatment from Day 7 to Day 35 following the completion of the counseling sessions and 
EMA procedures (EMA-Only no longer had access to the PPC). CDT consisted of three 
major modules: 1) Managing My Urge, 2) Treatment Information, and 3) Motivational 
Messages.
Managing My Urge included the questions defining the type of high-risk situation, the 
answers to which generated the 10 individualized, context-specific coping strategies for that 
situation (see EMA Tailoring Algorithm). If desired, the woman could re-order the strategies 
at any time based on new answers to efficacy and outcome expectation questions, and 
maintain the reordered sequence for the future. Thus, as the process of quitting progressed, 
each woman could modify her PPC-delivered treatment to better optimize the coping 
strategies presented for each type of high risk situation if desired.
Treatment Information consisted of: 1) General Information, and 2) Quitting Strategies. 
General Information provided guidance on topics such as the risks of smoking, benefits of 
quitting, understanding nicotine dependence and withdrawal, using the nicotine patch, and 
weight management. Quitting Strategies included specific tips on preparing to quit, coping 
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with urges and withdrawal, managing negative emotions, identifying high-risk situations, 
using deep breathing, and what to do if a lapse occurred.
Motivational Messages provided various messages of encouragement and support, such as: 
“Keep up the good work. Quitting is a process that takes time…” As many or as few 
messages could be viewed as the participant wished. The women could also program the 
PPC to automatically deliver a motivational message at self-selected times during the day.
Measures
Point-prevalence abstinence was defined as a self-report of no smoking during the previous 7 
days and a CO level of <10 ppm. Abstinence was assessed at every visit. The following 
questionnaires were administered to all participants prior to quitting. The Mood History 
Questionnaire (Spitzer, Kroenke, & Williams, 1999) assessed history of depression. The 
Demographic Information Questionnaire included age, gender, marital status, ethnicity, 
education, and occupation. The Fagerstrom Test for Nicotine Dependence (FTND; 
Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991) measured nicotine dependence. The 
Smoking Cessation History Questionnaire assessed previous quit attempts and nicotine use 
history.
Data Analysis
The efficacy of CDT versus EMA-Only was evaluated using longitudinal generalized linear 
mixed models regression (GLMM; McCulloch & Searle, 2001), specifically the GLIMMIX 
procedure implemented in SAS/STAT 9.1, across the Day 35, Month 6, and Month 12 
follow-ups for both completers only and intent-to-treat. Completers only analyses included 
all women with data for at least one of the three follow-ups. Only six of 302 participants did 
not provide data for at least one follow-up. Intent-to-treat analyses assumed that women with 
missing abstinence data for that follow-up had smoked (see Figure 1). All analyses included 
time as a covariate. Both unadjusted analyses, and adjusted analyses that controlled for age, 
race/ethnicity, education, partner status, cigarettes smoked per day, depression history, and 
abstinence at Day 7 (i.e., abstinence at the time of randomization), were conducted. The 
interaction of each of the pre-quit variables with treatment on abstinence was also examined. 
Process analyses within CDT participants examined the relationship between abstinence 
and: 1) usage of each of the three main modules (times accessed), and 2) total program 
usage (times accessed).
Results
Participant flow through the study is shown in Figure 1, and participant characteristics by 
group assignment are shown in Table 1. Overall, 97.4% (n=294) of the women attended all 
five counseling sessions and 2.6% (n=8) attended 4 of the 5 counseling sessions.
Abstinence rates by treatment group for both completers only and intent-to-treat across Day 
35, Month 6, and Month 12 are presented in Figure 2. GLMM analyses of biochemically 
verified 7 day point prevalence abstinence revealed no significant differences between CDT 
and EMA-Only for unadjusted completers only (OR= 0.89 (95% CI: 0.56–1.40); p = .60), 
unadjusted intent-to-treat (OR = 0.94 (95% CI: 0.60–1.46); p = .77), adjusted completers 
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only (OR = 0.77 (95% CI: 0.48–1.26) p = .32), or adjusted intent-to-treat analyses (OR = 
0.82 (95% CI: 0.51–1.32); p = .25). Among all participants, 74% reported no puff since quit 
date on Day 7. However, the treatment effect was not significant when controlling for 
abstinence status at Day 7, or among both complete abstainers at Day 7 or those individuals 
who smoked at least a puff by Day 7. The interaction between treatment and any smoking by 
Day 7 was examined, but it was not significant. There were no significant interactions 
between treatment and any of the pre-quit characteristics.
Process analyses investigated the relationship between the number of times a CDT 
participant accessed the overall program or a particular module and abstinence. Of the 151 
women randomized to CDT, all but six (96%) utilized the PPC during the treatment period. 
Table 2 shows wide variation in treatment usage. The relationship between Managing My 
Urge and abstinence approached significance for both completers only (OR = 1.02 (95% CI: 
0.99–1.03); p = .07) and intent to treat analyses (OR = 1.02 (95%CI: 0.99–1.03); p = .06). 
Additionally, the relationship between total PPC use and abstinence for completers only (OR 
= 1.01 (95% CI: 0.99–1.01); p = .09) approached significance. It is important to note that the 
change in odds is per CDT use. Women who had greater use of either the Managing My 
Urge module or of the total PPC program, tended to manifest higher rates of abstinence.
Additional analyses investigated whether any of the characteristics in Table 1 were 
associated with greater utilization of CDT. Greater tobacco consumption (cigarettes per day, 
CO level) was significantly associated with greater use of CDT. Specifically, greater 
cigarettes per day was correlated with greater usage of motivational messages (r=.22, p=.01), 
treatment information (r=.26, p=.003), and overall CDT use (r=.21, p=.01). Higher baseline 
CO values were correlated with greater usage of managing my urge (r=.25, p=.002), 
motivational messages (r=.28, p=.001), treatment information (r=.18, p=.04), and overall 
CDT use (r=.31, p<.001).
Discussion
The current study evaluated a PPC-delivered, theoretically-based, smoking relapse 
prevention intervention among women. Women are, arguably, at higher risk for smoking 
relapse and may particularly benefit from intervention efforts designed to prevent relapse. 
Treatment was tailored based on state of the science behavioral assessment methodology and 
provided real-time access to individualized, context-specific coping strategies, motivational 
messages, and general quitting and relapse prevention information via PPCs. Nevertheless, 
the PPC-delivered intervention did not improve abstinence rates relative to a standard 
treatment control group. There was at least a suggestion that among CDT participants, 
heavier smokers were more likely to utilize PPC-delivered treatment and that greater usage 
may be associated with more positive outcomes.
There are a number of factors that could have contributed to the nonsignificant findings. 
First, PPCs may simply be an ineffective methodology for delivering smoking relapse 
prevention interventions. However, a growing body of literature indicates that computer-
based interventions can improve smoking prevention and cessation outcomes (Brendryen, 
Drozd & Kraft, 2008; Norman, Maley, Li, & Skinner, 2008; Prokhorov et al., 2008; Rodgers 
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et al., 2005; Strecher et al., 2008b), including interventions delivered using mobile 
technology (Heron & Smyth, 2010). In addition, process analyses suggested that there may 
be an association between greater use of the PPC-delivered treatment, and of the Managing 
My Urge module in particular, and a decreased likelihood of relapse. However, these results 
only approached significance. Greater use of the treatment program was significantly 
correlated with greater tobacco consumption, and this association would tend to reduce the 
relationship between greater treatment usage and better outcomes. Unfortunately, we cannot 
determine the direction or meaningfulness of these results currently. For example, greater 
treatment usage could simply be an artifact of abstinence rather than a determinant of 
cessation success, or greater motivation to quit could increase both abstinence rates and 
treatment usage, creating a spurious relationship. Nevertheless, while the current study does 
not provide evidence for the efficacy of a PPC-delivered treatment, process analyses are at 
least suggestive of the need for more research on the development and evaluation of PPC-
delivered treatments.
Second, the use of the PPC to collect EMA data from all of the women prior to 
randomization could have turned the PPC into a conditioned cue for craving, leading to 
either an aversion to using CDT during high risk situations, or to reduced efficacy by 
activating craving processes through use of the PPC. In addition, EMA is burdensome and 
engaging in the EMA procedures for one week prior to receiving CDT may have created an 
aversion to using the PPC.
Third, the intensive EMA procedures, which included an average of 36 separate 
presentations of 10 context-specific coping strategies for one week postcessation, may have 
functioned as a coping-skills training intervention and diluted the experimental 
manipulation. In another study (Rowan et al., 2007), the identical EMA procedures alone did 
not increase abstinence relative to a group with no EMA, but that study was not adequately 
powered to detect differences in cessation. Nonetheless, future research would be well-
served by study designs that provide for better control of the various dimensions of PPC-
delivered interventions.
Fourth, the PPC-delivered intervention may have lacked appeal or have been too 
complicated in its current format as women used the program an average of less than 2 times 
per day. Recent results from an online tailored cessation program found that program 
engagement is important for improving outcomes (Strecher et al., 2008a). Participants may 
also have been unwilling or unable to effectively use the PPC when under duress, the time 
when intervention may be most needed.
Fifth, because all participants received intensive behavioral treatment and pharmacotherapy, 
abstinence rates were very high across both treatment groups at both Day 35 postcessation 
(61–64% for intent to treat) and at 12 months postcessation (25% for intent-to-treat). 
Therefore, the provision of a powerful multi-component treatment may have contributed to a 
ceiling effect. Given that PPC-delivered interventions are likely to be utilized in isolation in 
the real-world (e.g., smokers might download a program onto their smartphone), future 
research should evaluate PPC-delivered interventions used in isolation or as adjuvants to less 
intensive interventions.
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Finally, behavioral interventions based on social cognitive theory have not outperformed 
other treatment approaches (Carroll, 1996; Hajek, Stead, West, & Jarvis, 2005; Hajek, Stead, 
West, Jarvis, & Lancaster, 2009; Lancaster, Hajek, Stead, West, & Jarvis, 2006), nor has the 
track record for tailored interventions been universally positive (Lennox et al. 2001). The 
findings from the current study are consistent with those conclusions. Thus, it may be 
important to rethink how relapse prevention is addressed in future intervention research.
There are a number of limitations to the current research. The sample was largely White and 
consisted of women only. In addition, because both intervention content and delivery 
modality differed between CDT and ST, it was impossible to discern whether the null 
findings were attributable to content or modality. Further, there was intensive adjuvant 
treatment. Thus, the results should not be generalized to other populations or to other study 
approaches. To the best of our knowledge, this is one of the first studies to evaluate a 
theoretically grounded, PPC-delivered intervention in a well-controlled, randomized clinical 
trial. In particular, we are unaware of any other smoking cessation/relapse prevention studies 
that have utilized EMA data to individually tailor treatment. Although there are numerous 
theoretical and technical issues still to address in future research (e.g., assessment burden vs. 
tailoring specificity, increasing appeal and usage), the rapid pace of technological advances 
in mobile computer technology and the ubiquity of such devices provide a novel platform 
for the design and evaluation of new treatment approaches. Efficacy remains to be 
demonstrated however.
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Appendix: CONSORT checklist
PAPER SECTION And topic Item Description Reported on
Page #
TITLE & ABSTRACT 1 How participants were allocated to interventions 
(e.g., “random allocation”, “randomized”, or 
“randomly assigned”).
8
INTRODUCTION Background 2 Scientific background and explanation of rationale. 3–7
METHODS Participants 3 Eligibility criteria for participants and the settings 
and locations where the data were collected.
8–9
Interventions 4 Precise details of the interventions intended for 
each group and how and when they were actually 
administered.
13–14
Objectives 5 Specific objectives and hypotheses. 7
Outcomes 6 Clearly defined primary and secondary outcome 
measures and, when applicable, any methods used 
to enhance the quality of measurements (e.g., 
multiple observations, training of assessors).
15
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PAPER SECTION And topic Item Description Reported on
Page #
Sample size 7 How sample size was determined and, when 
applicable, explanation of any interim analyses 
and stopping rules.
9, 15
Randomization – Sequence 
generation
8 Method used to generate the random allocation 
sequence, including details of any restrictions 
(e.g., blocking, stratification)
9
Randomization – Allocation 
concealment
9 Method used to implement the random allocation 
sequence (e.g., numbered containers or central 
telephone), clarifying whether the sequence was 
concealed until interventions were assigned.
9
Randomization – Implementation 10 Who generated the allocation sequence, who 
enrolled participants, and who assigned 
participants to their groups.
9
Blinding (masking) 11 Whether or not participants, those administering 
the interventions, and those assessing the 
outcomes were blinded to group assignment. 
When relevant, how the success of blinding was 
evaluated.
9
Statistical methods 12 Statistical methods used to compare groups for 
primary outcome(s); Methods for additional 
analyses, such as subgroup analyses and adjusted 
analyses.
15–16
RESULTS Participant flow 13 Flow of participants through each stage (a diagram 
is strongly recommended). Specifically, for each 
group report the numbers of participants randomly 
assigned, receiving intended treatment, completing 
the study protocol, and analyzed for the primary 
outcome. Describe protocol deviations from study 
as planned, together with reasons.
16, 34, Figure 1
Recruitment 14 Dates defining the periods of recruitment and 
follow-up.
8
Baseline data 15 Baseline demographic and clinical characteristics 
of each group.
16, 32, Table 1
Numbers analyzed 16 Number of participants (denominator) in each 
group included in each analysis and whether the 
analysis was by “intention-to-treat”. State the 




Outcomes and estimation 17 For each primary and secondary outcome, a 
summary of results for each group, and the 




Ancillary analyses 18 Address multiplicity by reporting any other 
analyses performed, including subgroup analyses 
and adjusted analyses, indicating those pre-
specified and those exploratory.
16–19
Adverse events 19 All important adverse events or side effects in each 
intervention group.
NA
DISCUSSION Interpretation 20 Interpretation of the results, taking into account 
study hypotheses, sources of potential bias or 
imprecision and the dangers associated with 
multiplicity of analyses and outcomes.
19–23
Generalizability 21 Generalizability (external validity) of the trial 
findings.
23
Overall evidence 22 General interpretation of the results in the context 
of current evidence.
19–23
Wetter et al. Page 10














Bandura, A. Social Foundations of Thought and Action. New Jersey: Prentice Hall; 1986. 
Brandon TH, Tiffany ST, Obremski KM, Baker TB. Postcessation cigarette use: the process of relapse. 
Addictive Behaviors. 1990; 15(2):105–114. [PubMed: 2343783] 
Brendryen H, Drozd F, Kraft P. A digital smoking cessation program delivered through internet and 
cell phone without nicotine replacement (happy ending): randomized controlled trial. Journal of 
Medical Internet Research. 2008; 10(5):e51. [PubMed: 19087949] 
Carroll K. Relapse prevention as a psychosocial treatment: A review of controlled clinical trials. 
Experimental and Clinical Psychopharmacology. 1996; 4(1):46–54.
Carter, B.; Day, S.; Cinciripini, P.; Wetter, DW. Where are we and where are we going? The Science of 
Real-Time Data Capture: Self-Reports in Health Research. New York: Oxford University; 2007. 
Momentary health interventions; p. 289-307.
Drobes DJ, Elibero A, Evans DE. Attentional bias for smoking and affective stimuli: a Stroop task 
study. Psychology of Addictive Behaviors. 2006; 20(4):490–495. [PubMed: 17176185] 
Drobes DJ, Meier EA, Tiffany ST. Assessment of the effects of urges and negative affect on smokers’ 
coping skills. Behaviour Research and Therapy. 1994; 32(1):165–174. [PubMed: 8135716] 
Garvey AJ, Bliss RE, Hitchcock JL, Heinold JW, Rosner B. Predictors of smoking relapse among self-
quitters: a report from the Normative Aging Study. Addictive Behaviors. 1992; 17(4):367–377. 
[PubMed: 1502970] 
Gwaltney CJ, Shiffman S, Balabanis MH, Paty JA. Dynamic self-efficacy and outcome expectancies: 
prediction of smoking lapse and relapse. Journal of Abnormal Psychology. 2005; 114(4):661–675. 
[PubMed: 16351387] 
Hajek P, Stead LF, West R, Jarvis MJ. Relapse prevention interventions for smoking cessation. 
2005Cochrane Database System Review: CD003999
Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking 
cessation. 2009Cochrane Database System Review: CD003999
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine 
Dependence: a revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction. 
1991; 86(9):1119–1127. [PubMed: 1932883] 
Heron KE, Smyth JM. Ecological momentary interventions: Incorporating mobile technology into 
psychosocial and health behaviour treatments. British Journal of Health Psychology. 2010; 15:1–
39. [PubMed: 19646331] 
Lancaster T, Hajek P, Stead LF, West R, Jarvis MJ. Prevention of relapse after quitting smoking: a 
systematic review of trials. Archives of Internal Medicine. 2006; 166(8):828–835. [PubMed: 
16636207] 
Lennox AS, Osman LM, Reiter E, Robertson R, Friend J, McCann I, Skatun D, Donnan PT. Cost 
effectiveness of computer tailored and non-tailored smoking cessation letters in general practice. 
Randomised controlled trial. British Medical Journal. 2001; 322:1–7. [PubMed: 11141128] 
Marlatt, G.; Donovan, D., editors. Relapse prevention: Maintenance strategies in the treatment of 
addictive behaviors. 2nd. New York: Guilford Press; 2005. 
McCulloch, C.; Searle, S. Generalized, Linear, and Mixed Models. New York: John Wiley & Sons, Inc; 
2001. 
Norman CD, Maley O, Li X, Skinner HA. Using the internet to assist smoking prevention and 
cessation in schools: a randomized, controlled trial. Health Psychology. 2008; 27(6):799–810. 
[PubMed: 19025276] 
Prokhorov AV, Kelder SH, Shegog R, Murray N, Peters R Jr, Agurcia-Parker C, et al. Impact of A 
Smoking Prevention Interactive Experience (ASPIRE), an interactive, multimedia smoking 
prevention and cessation curriculum for culturally diverse high-school students. Nicotine & 
Tobacco Research. 2008; 10(9):1477–1485. [PubMed: 19023839] 
Rodgers A, Corbett T, Bramley D, Riddell T, Wills M, Lin RB, et al. Do u smoke after txt? Results of a 
randomised trial of smoking cessation using mobile phone text messaging. Tobacco Control. 2005; 
14(4):255–261. [PubMed: 16046689] 
Wetter et al. Page 11













Rowan PJ, Cofta-Woerpel L, Mazas CA, Vidrine JI, Reitzel LR, Cinciripini PM, Wetter DW. 
Evaluating reactivity to ecological momentary assessment during smoking cessation. Experimental 
and Clinical Psychopharmacology. 2007; 15(4):382–389. [PubMed: 17696685] 
Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? 
Pooled- and meta-analyses of clinical trials of bupropion SR. Addiction. 2004; 99(11):1462–1469. 
[PubMed: 15500599] 
Shiffman, S. Conceptual issues in the study of relapse. In: Gossop, M., editor. Relapse and Addictive 
Behaviour. Kent, England: Croom Helm, Ltd; 1989. p. 149-179.
Shiffman S. Dynamic influences on smoking relapse process. Journal of Personality. 2005; 73(6):
1715–1748. [PubMed: 16274451] 
Shiffman S. Reflections on smoking relapse research. Drug and Alcohol Review. 2006; 25(1):15–20. 
[PubMed: 16492573] 
Shiffman S, Balabanis MH, Paty JA, Engberg J, Gwaltney CJ, Liu KS, et al. Dynamic effects of self-
efficacy on smoking lapse and relapse. Health Psychology. 2000; 19(4):315–323. [PubMed: 
10907649] 
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the 
PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health 
Questionnaire. Journal of the American Medical Association. 1999; 282(18):1737–1744. 
[PubMed: 10568646] 
Spitzer, RL.; Williams, JB.; Kroenke, K.; Linzer, M.; deGruy, FV.; Hahn, SR. Primary care evaluation 
of mental disorders (PRIME-MD). New York: Pfizer Pharmaceuticals Group; 1995. 
Stone AA, Shiffman S. Ecological momentary assessment (EMA) in behavioral medicine. Annals of 
Behavioral Medicine. 1994; 16:199–202.
Strecher VJ, McClure J, Alexander G, Chakraborty B, Nair V, Konkel J, et al. The role of engagement 
in a tailored web-based smoking cessation program: randomized controlled trial. Journal of 
Medical Internet Research. 2008a; 10(5):e36. [PubMed: 18984557] 
Strecher VJ, McClure JB, Alexander GL, Chakraborty B, Nair VN, Konkel JM, et al. Web-based 
smoking-cessation programs: results of a randomized trial. American Journal of Preventative 
Medicine. 2008b; 34(5):373–381.
USDHHS. Women and smoking: A report of the surgeon general. Rockville, Maryland: U.S. 
Department of Health and Human Services, Public Health Service Office of the Surgeon General; 
2001. 
Walitzer KS, Dearing RL. Gender differences in alcohol and substance use relapse. Clinical 
Psychology Review. 2006; 26(2):128–148. [PubMed: 16412541] 
Wetter DW, Kenford SL, Smith SS, Fiore MC, Jorenby DE, Baker TB. Gender differences in smoking 
cessation. Journal of Consulting and Clinical Psychology. 1999; 67(4):555–562. [PubMed: 
10450626] 
Wetter et al. Page 12














Flow Diagram of Participants from Eligibility Assessment to Follow-up
Wetter et al. Page 13














Biochemically Confirmed 7 Day Point Prevalence Abstinence By Treatment Group
Note: EMA-Only = EMA-Only Treatment; CDT = Computer Delivered Treatment
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Table 1





(n = 151) p
Demographics
 Age 41.8 (10.4) 44.0 (11.2) 0.07
 Race
  % Caucasian 82.7 82.0
  % Hispanic 2.0 0
  % African American 8.0 6.7
  % Asian 3.3 2.7
  % Other 4.0 8.7 0.50
 % > high school education 78.1 74.2 0.25
 % professional occupation 51.6 51.3 0.53
 % with partner 43.6 35.8 0.17
Tobacco
 % abstinent at day 7 72.2 77.5 0.29
 Years smoked 22.6 (10.0) 24.6 (11.3) 0.10
 Cigarettes per day 20.6 (7.6) 20.5 (8.0) 0.94
 Fagerstrom Test for Nicotine Dependence 5.1 (1.9) 5.2 (2.0) 0.61
 % ≤5 5 min to 1st cig 34.4 37.3 0.34
 Baseline carbon monoxide level 22.7 (10.3) 23.7 (11.6) 0.43
 % partner smokes 51.8 41.1 0.12
Affect
 % with Depression History 30.7 31.3 0.50
Note: EMA-Only = EMA only treatment; CDT = computer-delivered treatment. Chi-square tests were used for categorical variables and two-tailed 
t-tests for continuous variables.
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Table 2
CDT Usage and its Relationship to Abstinence among CDT Participants (n=151)
Module % of participants who accessed 
module
Mean number of times 
accessed
(SD; range)
























Note: CDT = computer-delivered treatment.
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